Methods for treating antipsychotic-induced weight gain
The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient.
1. A method for treating schizophrenia, comprising orally administering, daily, to a patient need thereof, a pharmaceutical composition comprising:
olanzapine;
10 mg of a compound having the structure:
or a pharmaceutically acceptable salt thereof; and
a pharmaceutically acceptable excipient.
2. The method according to claim 1 , wherein the compound is present in the pharmaceutical composition as a pharmaceutically acceptable salt.
3. The method according to claim 1 , wherein the pharmaceutical composition is a tablet.
4. The method according to claim 1 , wherein the pharmaceutical composition further comprises lactose.
5. The method according to claim 1 , wherein the pharmaceutical composition further comprises magnesium stearate.
6. The method according to claim 5 , wherein the pharmaceutical composition further comprises lactose.
7. A method for treating schizophrenia in patient in need thereof comprising:
orally administering daily to the patient 10 mg, based on the free base weight, a compound having the structure:
or a pharmaceutically acceptable salt thereof; and
administering to the patient, daily, an antipsychotic, wherein the antipsychotic is olanzapine.
8. The method according to claim 7 , wherein administering the compound and administering the olanzapine occurs concurrently.
9. The method according to claim 7 , wherein the compound is present in the pharmaceutical composition as a pharmaceutically acceptable salt.
10. A method for treating schizophrenia in a patient in need thereof, comprising orally administering, daily, to a patient, a pharmaceutical composition comprising:
10 mg, based on the free base weight, of a compound having the structure:
olanzapine; and
a pharmaceutically acceptable excipient;
wherein the compound is present in the pharmaceutical composition as a pharmaceutically acceptable salt.
11. The method according to claim 10 , wherein the pharmaceutical composition is a tablet.